Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize Sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.

Acumen Pharmaceuticals Inc.

Acumen Pharmaceuticals ( ($ABOS) ) has shared an announcement. On November 10, 2025, Acumen Pharmaceuticals announced the appointment of Dr. George...

Current Quarter	$-0.63	Next Quarter	$NA
Current Year	$-2.24	Next Year	$-1.58
QoQ Growth	NaN%	YoY Growth	+29.5%
3Y EPS CAGR	+30.2%	Target Price	$6.75
Consensus	Buy	Upside	+329.9%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ABOS	$1.57	+0.64%	82.62K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ABOS	$1.57	+0.6%	82.62K
3
4
5
6

ABOS

ABOS

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Acumen Pharmaceuticals Inc. Data in Excel

Get Acumen Pharmaceuticals Inc. Data in Excel